NewsHomeNewsNews02/09/2218/07/24Pfizer’s First Dual Indication Vaccine for Respiratory Syncytial Virus (RSV) is Available This Month in Hong Kong 08/05/24Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong 29/09/23Rimegepant is Now Available in Hong Kong, the First Market in Asia, for Migraine Management 10/08/23Pfizer’s Pneumococcal 20-Valent Conjugate Vaccine is Now Available in Hong Kong, For Adults Aged 18 Years or Older 02/09/22Bank Of China Group Insurance and Pfizer Hong Kong Announce Partnership to Increase Health Literacy26/08/22Pfizer Ranked Leading Company in Asia For Covid-19 Response And Patient-Centric Approach By Asian Patient Groups27/11/19Hong Kong Business Management Excellence Awards 2019 Team of the Year-Pharmaceuticals24/05/19Pfizer Hong Kong Receives "Joyful@Healthy Workplace" Awards24/05/19Pfizer Hong Kong Receives "Caring Company" award for 17th Straight Year (2002-2019)08/08/18Pfizer Hong Kong Receives "HR Asia Best Companies to Work for in Asia 2018" Award05/04/18Pfizer Hong Kong Awarded as “Caring Company” for 16th Straight Year (2002-2018)01/03/18Pfizer Hong Kong Received "Joyful@Healthy Workplace" Awards07/10/16Pfizer Hong Kong Wins the Asia Best Employer Brand Awards 201627/05/16Pfizer Hong Kong Receives "HR Asia Best Companies to Work for in Asia 2016" Award10/01/16Pfizer Hong Kong won the Hong Kong Outstanding Corporate Citizenship Gold Award31/12/15Pfizer Hong Kong Won the Happy Company Award31/12/15Pfizer Hong Kong Won the Asia Best Employer Brand Awards18/12/12Pfizer Hong Kong Receives Most Admired Knowledge Enterprise (MAKE) Award12/03/12Pfizer Hong Kong is Recognized with ‘Caring Company – 10 Consecutive Years’ Title06/07/09Pfizer Hong Kong Awarded 2009 Hong Kong Management Association Quality Award - Gold Award23/04/09Pfizer Partners with Hong Kong Science Park to Increase Capabilities of Regional Biotechnology Sector